A two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab

Antibodies (mAbs) and antibody fragments (Fabs) constitute one of the largest and most rapidly expanding groups of protein pharmaceuticals. In particular, antibody fragments have certain advantages over mAbs in some therapeutic settings. However, due to their greater chemical diversity, they are mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatli, Ozge, Oz, Yagmur, Dingiloglu, Baran, Yalcinkaya, Duygu, Basturk, Ezgi, Korkmaz, Melis, Akbulut, Latif, Hatipoglu, Derya, Kirmacoglu, Cansin, Akgun, Buse, Turk, Kubra, Pinar, Orkun, Sariyar Akbulut, Berna, Atabay, Zeynep, Tahir Turanli, Eda, Kazan, Dilek, Dinler Doganay, Gizem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651443/
https://www.ncbi.nlm.nih.gov/pubmed/38027967
http://dx.doi.org/10.1016/j.heliyon.2023.e21001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651443/
https://www.ncbi.nlm.nih.gov/pubmed/38027967
http://dx.doi.org/10.1016/j.heliyon.2023.e21001

Ejemplares similares